The favorable efficacy and safety profile emerging from our cohort is similar to that reported in the increasing number of studies addressing the use of TPO-RA in myeloid neoplasms (mainly MDS, but also acute myeloid leukemia and chronic myelomonocytic leukemia), in the postchemotherapy setting of solid tumors, in secondary ITP (associated to both lymphoproliferative syndromes or systemic lupus erythematosus), in graft failure after HSCT, in thrombocytopenia after heart and lung transplantation, in chronic liver diseases, and in inherited thrombocytopenia (Table 2). Here, TPO is linked to chronic myelomonocytic leukemia.